Financhill
Sell
44

BIOA Quote, Financials, Valuation and Earnings

Last price:
$4.37
Seasonality move :
--
Day range:
$4.26 - $4.53
52-week range:
$2.88 - $26.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.49x
Volume:
157.4K
Avg. volume:
280.5K
1-year change:
--
Market cap:
$154.2M
Revenue:
--
EPS (TTM):
-$8.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIOA
Bioage Labs
$556.7K -$0.53 -60.03% -15.72% $6.00
ALUR
Allurion Technologies
$5.5M -$1.57 -47.31% -28.8% $10.63
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -55.87% $14.2692
IART
Integra Lifesciences Holdings
$381.2M $0.43 -5.53% 241.78% $16.13
RSLS
Reshape Lifesciences
$2.1M -$9.28 -- -- --
TMCI
Treace Medical Concepts
$52.1M -$0.30 5.9% -21.86% $9.73
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIOA
Bioage Labs
$4.30 $6.00 $154.2M -- $0.00 0% --
ALUR
Allurion Technologies
$2.71 $10.63 $20.2M -- $0.00 0% 0.31x
CATX
Perspective Therapeutics
$3.2300 $14.2692 $239.8M -- $0.00 0% 22.77x
IART
Integra Lifesciences Holdings
$13.88 $16.13 $1.1B 70.14x $0.00 0% 0.66x
RSLS
Reshape Lifesciences
$2.60 -- $1.9M 0.01x $0.00 0% 0.01x
TMCI
Treace Medical Concepts
$5.90 $9.73 $371.1M -- $0.00 0% 1.74x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIOA
Bioage Labs
2.2% 0.000 5.23% 13.52x
ALUR
Allurion Technologies
-79.73% -2.152 161.73% 1.81x
CATX
Perspective Therapeutics
-- -0.117 -- --
IART
Integra Lifesciences Holdings
54.74% 1.009 107.86% 0.57x
RSLS
Reshape Lifesciences
-- 2.802 -- 0.79x
TMCI
Treace Medical Concepts
33.65% 4.109 10.12% 3.23x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIOA
Bioage Labs
-- -$16.4M -- -- -873.4% -$17.8M
ALUR
Allurion Technologies
$4.2M -$7.3M -- -- 133.94% -$9.5M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
IART
Integra Lifesciences Holdings
$194.4M -$15.5M -0.86% -1.88% -2.93% -$40.2M
RSLS
Reshape Lifesciences
$681K -$1.8M -159.67% -172.58% -165.23% -$2.1M
TMCI
Treace Medical Concepts
$41.9M -$15.6M -32% -47.17% -27.79% $655K

Bioage Labs vs. Competitors

  • Which has Higher Returns BIOA or ALUR?

    Allurion Technologies has a net margin of -890.97% compared to Bioage Labs's net margin of -367.88%. Bioage Labs's return on equity of -- beat Allurion Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOA
    Bioage Labs
    -- -$0.36 $320.2M
    ALUR
    Allurion Technologies
    74.57% $0.20 -$38.8M
  • What do Analysts Say About BIOA or ALUR?

    Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Allurion Technologies has an analysts' consensus of $10.63 which suggests that it could grow by 292.07%. Given that Allurion Technologies has higher upside potential than Bioage Labs, analysts believe Allurion Technologies is more attractive than Bioage Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOA
    Bioage Labs
    0 3 1
    ALUR
    Allurion Technologies
    2 1 0
  • Is BIOA or ALUR More Risky?

    Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Allurion Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIOA or ALUR?

    Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allurion Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Allurion Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOA or ALUR?

    Bioage Labs quarterly revenues are $1.5M, which are smaller than Allurion Technologies quarterly revenues of $5.6M. Bioage Labs's net income of -$12.9M is lower than Allurion Technologies's net income of $7.4M. Notably, Bioage Labs's price-to-earnings ratio is -- while Allurion Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.31x for Allurion Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOA
    Bioage Labs
    -- -- $1.5M -$12.9M
    ALUR
    Allurion Technologies
    0.31x -- $5.6M $7.4M
  • Which has Higher Returns BIOA or CATX?

    Perspective Therapeutics has a net margin of -890.97% compared to Bioage Labs's net margin of --. Bioage Labs's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOA
    Bioage Labs
    -- -$0.36 $320.2M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About BIOA or CATX?

    Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.2692 which suggests that it could grow by 341.77%. Given that Perspective Therapeutics has higher upside potential than Bioage Labs, analysts believe Perspective Therapeutics is more attractive than Bioage Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOA
    Bioage Labs
    0 3 1
    CATX
    Perspective Therapeutics
    10 1 0
  • Is BIOA or CATX More Risky?

    Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

  • Which is a Better Dividend Stock BIOA or CATX?

    Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOA or CATX?

    Bioage Labs quarterly revenues are $1.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Bioage Labs's net income of -$12.9M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Bioage Labs's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 22.77x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOA
    Bioage Labs
    -- -- $1.5M -$12.9M
    CATX
    Perspective Therapeutics
    22.77x -- -- -$18.2M
  • Which has Higher Returns BIOA or IART?

    Integra Lifesciences Holdings has a net margin of -890.97% compared to Bioage Labs's net margin of -6.61%. Bioage Labs's return on equity of -- beat Integra Lifesciences Holdings's return on equity of -1.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOA
    Bioage Labs
    -- -$0.36 $320.2M
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
  • What do Analysts Say About BIOA or IART?

    Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 16.17%. Given that Bioage Labs has higher upside potential than Integra Lifesciences Holdings, analysts believe Bioage Labs is more attractive than Integra Lifesciences Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOA
    Bioage Labs
    0 3 1
    IART
    Integra Lifesciences Holdings
    2 5 2
  • Is BIOA or IART More Risky?

    Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

  • Which is a Better Dividend Stock BIOA or IART?

    Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOA or IART?

    Bioage Labs quarterly revenues are $1.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Bioage Labs's net income of -$12.9M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Bioage Labs's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.66x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOA
    Bioage Labs
    -- -- $1.5M -$12.9M
    IART
    Integra Lifesciences Holdings
    0.66x 70.14x $382.7M -$25.3M
  • Which has Higher Returns BIOA or RSLS?

    Reshape Lifesciences has a net margin of -890.97% compared to Bioage Labs's net margin of -68.98%. Bioage Labs's return on equity of -- beat Reshape Lifesciences's return on equity of -172.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOA
    Bioage Labs
    -- -$0.36 $320.2M
    RSLS
    Reshape Lifesciences
    61.19% $474.50 $1.2M
  • What do Analysts Say About BIOA or RSLS?

    Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 55669.16%. Given that Reshape Lifesciences has higher upside potential than Bioage Labs, analysts believe Reshape Lifesciences is more attractive than Bioage Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOA
    Bioage Labs
    0 3 1
    RSLS
    Reshape Lifesciences
    0 0 0
  • Is BIOA or RSLS More Risky?

    Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.358%.

  • Which is a Better Dividend Stock BIOA or RSLS?

    Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOA or RSLS?

    Bioage Labs quarterly revenues are $1.5M, which are larger than Reshape Lifesciences quarterly revenues of $1.1M. Bioage Labs's net income of -$12.9M is lower than Reshape Lifesciences's net income of $1.5M. Notably, Bioage Labs's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is 0.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.01x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOA
    Bioage Labs
    -- -- $1.5M -$12.9M
    RSLS
    Reshape Lifesciences
    0.01x 0.01x $1.1M $1.5M
  • Which has Higher Returns BIOA or TMCI?

    Treace Medical Concepts has a net margin of -890.97% compared to Bioage Labs's net margin of -30.29%. Bioage Labs's return on equity of -- beat Treace Medical Concepts's return on equity of -47.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOA
    Bioage Labs
    -- -$0.36 $320.2M
    TMCI
    Treace Medical Concepts
    79.69% -$0.25 $158.8M
  • What do Analysts Say About BIOA or TMCI?

    Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 39.54%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 64.89%. Given that Treace Medical Concepts has higher upside potential than Bioage Labs, analysts believe Treace Medical Concepts is more attractive than Bioage Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOA
    Bioage Labs
    0 3 1
    TMCI
    Treace Medical Concepts
    2 5 0
  • Is BIOA or TMCI More Risky?

    Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIOA or TMCI?

    Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOA or TMCI?

    Bioage Labs quarterly revenues are $1.5M, which are smaller than Treace Medical Concepts quarterly revenues of $52.6M. Bioage Labs's net income of -$12.9M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, Bioage Labs's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 1.74x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOA
    Bioage Labs
    -- -- $1.5M -$12.9M
    TMCI
    Treace Medical Concepts
    1.74x -- $52.6M -$15.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will VICI Properties Be in 5 Years?
Where Will VICI Properties Be in 5 Years?

VICI Properties (NYSE:VICI) is a real estate investment trust focused…

Where Will Exxon Stock Be in 5 Years?
Where Will Exxon Stock Be in 5 Years?

For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…

How High Will Dollar General Stock Go?
How High Will Dollar General Stock Go?

Shares of Dollar General (NYSE:DG) have risen significantly in recent…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
64
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
59
SBET alert for Jun 10

SharpLink Gaming [SBET] is up 14.34% over the past day.

Buy
85
ASTS alert for Jun 10

AST SpaceMobile [ASTS] is up 2.58% over the past day.

Buy
69
CCJ alert for Jun 10

Cameco [CCJ] is down 4.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock